The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor
Open accessAbstract
Human genetic data have associated angiotensin-converting enzyme (ACE) with Alzheimer disease (AD), and purified ACE has been reported to cleave synthetic amyloid beta-protein (Abeta) in vitro. Whether deficiency in ACE activity, arising from genetic alteration or pharmacological inhibition, can decrease Abeta degradation and allow Abeta accumulation in intact cells is unknown. We cloned ACE from human neuroblastoma cells and showed that it had posttranslational processing and enzymatic activity typical of the endogenous protease. Cellular expression of ACE promoted degradation of naturally secreted Abeta40 and Abeta42, leading to significant clearance of both species. Using site-directed mutagenesis, we determined that both active sites within ACE contribute to Abeta clearance, and an ACE construct bearing mutations in each catalytic domain had no effect on Abeta levels. Pharmacological inhibition of ACE with a widely prescribed drug, captopril, promoted the accumulation of cell-derived Abeta in the media of beta-amyloid precursor-protein expressing cells. Together, these results show that ACE can lower the levels of secreted Abeta in living cells and that this effect is blocked by inhibiting the protease's activity with an ACE inhibitor. This work, combined with the genetic studies, supports the hypothesis that ACE may modulate the susceptibility to and progression of AD via degradation of Abeta. Our data encourage further analyses of the ACE gene for disease association and raise the question of whether currently prescribed ACE inhibitors could elevate cerebral Abeta levels in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286
Self-citationDeciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Self-citationMetabolic Regulation of Brain Aβ by Neprilysin
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H.-J., & Saido, T. C. (2001) · Science · doi:10.1126/science.1059946 · Cited by 961
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777
Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00787-6 · Cited by 719
Self-citation(1997) · doi:10.1073/pnas.94.4.1550 · Cited by 535
Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R., & Selkoe, D. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-05-01657.2000 · Cited by 495
Self-citation
Cited by
The Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 381
Bernstein, K. E., Ong, F. S., Blackwell, W.-L. B., Shah, K. H., Giani, J. F., Gonzalez-Villalobos, R. A., Shen, X. Z., & Fuchs, S. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006809 · Cited by 324
β-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease
Sun, X., Chen, W.-D., & Wang, Y.-D. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00221 · Cited by 323
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 304
Cerebrovascular disease in ageing and Alzheimer’s disease
Love, S., & Miners, J. S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1522-0 · Cited by 299
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Neurobiology of Alzheimer′s disease
Mohandas, E., Rajmohan, V, & Raghunath, B. (2009) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.44908 · Cited by 268
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Modifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196
Markers and Biomarkers of Endothelium: When Something Is Rotten in the State
Goncharov, N. V., Nadeev, A. D., Jenkins, R. O., & Avdonin, P. V. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9759735 · Cited by 190
“On average, only 20% of capillary ECs in each organ stains for ACE, with the exception of the lung and kidney.”
BackgroundThe Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease
Stakos, D. A., Stamatelopoulos, K., Bampatsias, D., Sachse, M., Zormpas, E., Vlachogiannis, N. I., Tual-Chalot, S., & Stellos, K. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.033 · Cited by 188
“Inhibition of the angiotensin-converting enzyme increases Ab1-40 or Ab1-42 availability due to attenuation of its breakdown (65) or through blockade of Ab1-42 conversion to Ab1-40 (65), respectively.”
BackgroundAre amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
(2009) · PubMed Central · Cited by 165
The involvement of lipid rafts in Alzheimer's disease (Review)
Cordy, J. M., Cordy, J. M., Hooper, N. M., & Turner, A. J. (2006) · Molecular Membrane Biology · doi:10.1080/09687860500496417 · Cited by 157
Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements
Hemming, M. L., Elias, J. E., Gygi, S. P., & Selkoe, D. J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060257 · Cited by 153
Self-citationAlzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Brain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty
Cosarderelioglu, C., Nidadavolu, L. S., George, C. J., Oh, E. S., Bennett, D. A., Walston, J. D., & Abadir, P. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586314 · Cited by 134
“Although ACE was shown to degrade Aβ peptide (Hemming and Selkoe, 2005), it can also degrade neprilysin, an Aβ-degrading enzyme that may contribute to Aβ aggregation (Carson and Turner, 2002).”
BackgroundKehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133
Kauwe, J. S. K., Bailey, M. H., Ridge, P. G., Perry, R., Wadsworth, M. E., Hoyt, K. L., Staley, L. A., Karch, C. M., Harari, O., Cruchaga, C., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004758 · Cited by 125
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
AbdAlla, S., Langer, A., Fu, X., & Quitterer, U. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816917 · Cited by 100
Bild, W., Hritcu, L., Stefanescu, C., & Ciobica, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.009 · Cited by 83
The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease
Jochemsen, H. M., Teunissen, C. E., Ashby, E. L., van der Flier, W. M., Jones, R. E., Geerlings, M. I., Scheltens, P., Kehoe, P. G., & Muller, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt257 · Cited by 77
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
Meng, Y., Baldwin, C. T., Bowirrat, A., Waraska, K., Inzelberg, R., Friedland, R. P., & Farrer, L. A. (2006) · The American Journal of Human Genetics · doi:10.1086/503687 · Cited by 72
The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI)
Vadhan, J. D., & Speth, R. C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107684 · Cited by 42
Madadi, S., Schwarzenbach, H., Saidijam, M., Mahjub, R., & Soleimani, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0354-3 · Cited by 41
Danziger, R., Fuchs, D.-T., Koronyo, Y., Rentsendorj, A., Sheyn, J., Hayden, E. Y., Teplow, D. B., Black, K. L., Fuchs, S., Bernstein, K. E., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1179315 · Cited by 16
Ongali, B., Nicolakakis, N., Tong, X.-K., Aboulkassim, T., Imboden, H., & Hamel, E. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150868 · Cited by 16
“Previous data have claimed ACE benefits in the degradation of A peptide in AD [61, 62] and argued that the inhibition of this enzyme may eventually prove counterproductive when administered over prolonged periods [14, 63].”
BackgroundLi, Y., Zhang, Z., Deng, L., Bai, F., Shi, Y., Yu, H., Xie, C., Yuan, Y., & Zhang, Z. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.06.026 · Cited by 15
Metadata
- Authors
- Hemming, M. L., & Selkoe, D. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-11
- Volume
- 280
- Issue
- 45
- Pages
- 37644-37650
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1999061258
- Cited by
- 332
- References
- 44
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.